Phase 4 N=100 SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)
Asthma
Primary: Number of Participants in Each Arm With a Need for an Increase in Study Medication — 29; 29 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=37 Anterior Insula Regulation and Pain Empathy
Anterior Insula Activity During Regulation · Empathic Responses After Anterior Insula Regulation
Primary: Neural Activity of Anterior Insula During Neorofeedback Training — 0.077; 0.026 percentage of BOLD signal change
Phase 4 N=125 24-hr Intraocular Pressure Control With SIMBRINZA ®
Glaucoma
Primary: Least Squares Mean Change From Baseline in 24-hr Intraocular Pressure (IOP) at Week 4 — -3.09; -0.60 mmHg
Phase 2 N=602 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Six Minute Walk Distance (6MWD) at Week 4, 12 and 24 — 314.4; 311.8; 313.2; 319.9 Meter (m) — p=0.517
Phase 2 N=84 Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART
HIV-1 Infection
Primary: Etonogestrel Concentrations at Study Day 21 — 1860.00; 429.00; 3290.00 pg/mL — p=<0.001
Phase 2 N=64 Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Chronic Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Responder Rate (RR) to Avatrombopag on Day 28 — 13.3; 53.3; 50.0; 80.0 Percentage of participants
Phase 3 N=970 GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Hypercholesterolemia
Primary: Change From Baseline in Percent Atheroma Volume at Week 78 — 0.053; -0.955 percent atheroma volume — p=< 0.0001
Phase 2 N=131 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
Cystitis, Interstitial · Painful Bladder Syndrome
Primary: Change From Baseline in Daily Average Bladder Pain to Treatment 1 Week 4 Follow-up — -1.2; -1.5 score on a scale — p=0.505
Phase 3 N=38 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Lambert Eaton Myasthenic Syndrome
Primary: Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 Days — 5.6; 6.4; 7.9; 6.7 QMG Score — p=0.0452
Phase 2 N=61 Heart Rate Variability in Response to Metformin Challenge
Fibromyalgia · Mitochondrial Diseases · Movement Disorders
Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77
Phase 3 N=112 Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media
Acute Otitis Media
Primary: The Distribution of Participants Receiving Formulation 1 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product — 10; 30 Participants
Phase 1 N=36 Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adj of L-Praziquantel (L-PZQ) After Dose Adjustment — 825.2; 2066.0; 216.7…
N/A N=283 Open Abdomen Study Comparing ABThera™ Open Abdomen Negative Pressure Therapy System and Barker's Vacuum Packing Technique
Open Abdomen
Primary: Number of Participants With Primary Fascial Closure — 139; 69 Participants — p=0.06
N/A N=276 Micra Transcatheter Pacing System Continued Access Study Protocol
Bradycardia
Primary: Complications — 4 % participants with complication
Phase 4 N=72 Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
HIV-1 Infection
Primary: Actual Glomerular Filtration Rate (aGFR) Using Iohexol Plasma Clearance (CLiohexol) at Week 24 — 103.6; 104.9; 111.1; 101.0 mL/min